Kovacs, K., Scheithauer, B. W., Lombardero, M., McLendon, R. E., Syro, L. V., Uribe, H., … Penagos, L. C. (2008). MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol, 115(2), 261–262. https://doi.org/10.1007/s00401-007-0279-5

Kovacs, Kalman, Bernd W. Scheithauer, Matilde Lombardero, Roger E. McLendon, Luis V. Syro, Humberto Uribe, Leon D. Ortiz, and Luis C. Penagos. “MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.” Acta Neuropathol 115, no. 2 (February 2008): 261–62. https://doi.org/10.1007/s00401-007-0279-5.

Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, et al. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 2008 Feb;115(2):261–2.

Kovacs, Kalman, et al. “MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.” Acta Neuropathol, vol. 115, no. 2, Feb. 2008, pp. 261–62. Pubmed, doi:10.1007/s00401-007-0279-5.

Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol. 2008 Feb;115(2):261–262.